Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Payables (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Payables readings, the most recent being $418000.0 for Q4 2017.

  • On a quarterly basis, Payables fell 88.96% to $418000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $418000.0, a 88.96% decrease, with the full-year FY2017 number at $418000.0, down 88.96% from a year prior.
  • Payables hit $418000.0 in Q4 2017 for Eledon Pharmaceuticals, up from $189000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.8 million in Q4 2016 to a low of $5000.0 in Q4 2013.
  • Median Payables over the past 5 years was $1.2 million (2015), compared with a mean of $1.4 million.
  • Biggest five-year swings in Payables: surged 15200.0% in 2014 and later tumbled 88.96% in 2017.
  • Eledon Pharmaceuticals' Payables stood at $5000.0 in 2013, then surged by 15200.0% to $765000.0 in 2014, then skyrocketed by 57.91% to $1.2 million in 2015, then soared by 213.33% to $3.8 million in 2016, then tumbled by 88.96% to $418000.0 in 2017.
  • The last three reported values for Payables were $418000.0 (Q4 2017), $189000.0 (Q3 2017), and $374000.0 (Q2 2017) per Business Quant data.